STOCK TITAN

Ginkgo Bioworks Announces Date of Second Quarter 2022 Results Presentation

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Presentation and Q&A session scheduled for post-market on Monday, August 15, 2022

BOSTON, Aug. 8, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2022, on Monday, August 15, 2022, beginning at 4:30 p.m. ET.

The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.

To ask a question ahead of the presentation, please submit them to @Ginkgo on Twitter (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.

About Ginkgo Bioworks

Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. For more information, visit https://www.ginkgobioworks.com/.

Ginkgo Bioworks Contacts:

INVESTOR CONTACT:

investors@ginkgobioworks.com     

MEDIA CONTACT:

press@ginkgobioworks.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-date-of-second-quarter-2022-results-presentation-301601471.html

SOURCE Ginkgo Bioworks

Ginkgo Bioworks Holdings Inc

NYSE:DNA

DNA Rankings

DNA Latest News

DNA Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link

About DNA

the organism company ginkgo bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. our biological engineers make use of an in-house pipeline of synthetic biology technologies to design, build, and test new organisms.